CR 13626
Alternative Names: CR-13626Latest Information Update: 28 Feb 2024
At a glance
- Originator Rottapharm Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-fyn inhibitors; Vascular endothelial growth factor receptor-2 antagonists; YAP1 (Yes-associated) protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Glioblastoma
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 28 Feb 2024 Preclinical development is ongoing in Italy for Glioblastoma
- 28 Oct 2023 No recent reports of development identified for preclinical development in Glioblastoma in Italy (PO)
- 18 Sep 2019 CR 13626 is available for licensing as of 18 Sep 2019. http://www.rottapharmbiotech.com/pipeline/